A randomized comparison of efficacy and safety of intralesional triamcinolone injection and clobetasol propionate ointment for psoriatic nails

2018 ◽  
Vol 30 (2) ◽  
pp. 117-122 ◽  
Author(s):  
Einapak Boontaveeyuwat ◽  
Narumol Silpa-Archa ◽  
Nasuda Danchaivijitr ◽  
Chanisada Wongpraparut
Keyword(s):  
Clobetasol Propionate ◽  
Efficacy And Safety ◽  
Triamcinolone Injection

scholarly journals Efficacy and safety of intralesional triamcinolone acetonide in the treatment of chronic hand eczema

2017 ◽  
Vol 10 (3) ◽  
pp. 129
Author(s):  
Tasnuva Ashraf ◽  
Harashit Kumar Paul ◽  
Md. Shahidullah Sikder ◽  
A. S. M. Zakaria ◽  
Saiful Islam Bhuiyan ◽  
...  
Keyword(s):  
Triamcinolone Acetonide ◽  
Severity Index ◽  
Hand Eczema ◽  
Clobetasol Propionate ◽  
Controlled Clinical Trial ◽  
Efficacy And Safety ◽  
Randomized Controlled ◽  
Chronic Hand Eczema ◽  
Group A ◽  
Group B

<p class="Abstract">This randomized controlled clinical trial was conducted to assess the efficacy and safety of intralesional triamcinolone acetonide in the treatment of chronic hand eczema comparing with topical clobetasol propionate. A total 60 patients of chronic hand eczema were recruited in the study. Thirty patients (Group A) were treated with intralesional triamcinolone acetonide and the rest 30 (Group B) with topical clobetasol propionate. Severity and improvement were assessed using Hand Eczema Severity Index (HECSI) score. The patients of both groups were followed up at 4<sup>th</sup> week and 12<sup>th</sup> week. In Group A, median HECSI score at baseline, 4<sup>th</sup> week and 12<sup>th</sup> week were 3, 20 and 20 respectively; whereas these scores were 54, 10 and 8 in Group B. In both groups, HECSI score was decreased gradually but the rate was higher in Group B than Group A (p&lt;0.05). Thinning of skin, an adverse effect, was seen in patients of both the intralesional triamcinolone acetonide (10%) and topical clobetasol propionate (16.7%) groups (p&gt;0.05). The result of this study demonstrates that intralesional triamcinolone acetonide is effective and safe in treating chronic hand eczema but less effective than the topical clobetasol.</p>

Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: A randomized comparison of efficacy and safety in subjects with scalp psoriasis

2005 ◽  
Vol 16 (1) ◽  
pp. 31-36 ◽  
Author(s):  
P. Reygagne ◽  
U. Mrowietz ◽  
J. Decroix ◽  
F. B. de Waard‐van der Spek ◽  
L. Olmos Acebes ◽  
...  
Keyword(s):  
Clobetasol Propionate ◽  
Efficacy And Safety ◽  
Scalp Psoriasis

scholarly journals Efficacy and Safety of Endoscopic Intralesional Triamcinolone Injection for Benign Esophageal Strictures

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Ya-Wu Zhang ◽  
Feng-Xian Wei ◽  
Xue-Ping Qi ◽  
Zhao Liu ◽  
Xiao-Dong Xu ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Cochrane Collaboration ◽  
Cochrane Library ◽  
Efficacy And Safety ◽  
Stricture Rate ◽  
Increased Risk ◽  
Esophageal Strictures ◽  
Triamcinolone Injection ◽  
The Cochrane Collaboration ◽  
The Cochrane Library

Objectives.To evaluate the efficacy and safety of endoscopic intralesional triamcinolone injection (ITI) for benign esophageal strictures combined with endoscopic dilation (ED).Methods.Online databases including MEDLINE, EMBASE, the Cochrane Library, and Web of Science were comprehensively searched for prospective randomized control trials (RCTs) between 1966 and March 2018. A meta-analysis was conducted according to the methods recommended by the Cochrane Collaboration.Results.Six RCTs consisting of 176 patients were selected. Meta-analysis results showed that additional ITI had a significant advantage in terms of stricture rate and required ED sessions. Surgery-related and non-surgery-related strictures showed similar results. Additional ITI was not associated with significantly increased risk of complications.Conclusions. Our meta-analysis showed that additional ITI therapy was supposed to be effective and safe for benign esophageal strictures as it reduced the stricture rate and required ED sessions. However, more RCTs are necessary to support these findings.

scholarly journals Efficacy and Safety of Novel Formulation of Clobetasol Propionate 0.025% Cream in Indian Moderate-to-Severe Psoriasis Patients: Phase-2a, Randomized 3-Arm Study

2021 ◽  
Author(s):  
Srinivas Sidgiddi ◽  
Syed Mujtaba Hussain Naqvi ◽  
Manjunath Shenoy ◽  
Devang Narayan Balraj ◽  
Jayesh Kothari ◽  
...  
Keyword(s):  
Clobetasol Propionate ◽  
Severe Psoriasis ◽  
Efficacy And Safety

scholarly journals Pharmacotherapy of Inflammatory and Pruritic Manifestations of Corticosteroid-Responsive Dermatoses Focus on Clobetasol Propionate

2010 ◽  
Vol 2 ◽  
pp. CMT.S1993 ◽  
Author(s):  
Anna Zampetti ◽  
Claudio Feliciani ◽  
Antonello Tulli ◽  
Pierluigi Amerio
Keyword(s):  
Quality Of Life ◽  
Atopic Dermatitis ◽  
Safety Profile ◽  
Topical Treatment ◽  
Clobetasol Propionate ◽  
Topical Steroids ◽  
Efficacy And Safety ◽  
Short Term ◽  
Chronic Eczema

Clobetasol-17 propionate is a dihalogenated corticosteroid which, on the basis of the vasoconstrictor assay, is classified as the most potent of all topical steroids. Since 1973 it has been marketed specifically for the short term topical treatment of moderate and severe cortico-responsive dermatoses for its antinflammatory, immunosuppressive and antimitotic effects. Psoriasis, atopic dermatitis, chronic eczema, boullous disorders and itching dermatosis of the genital area are usually well controlled by clobetasol with a great improvement of quality of life in patients. In this manuscript, we reviewed data concerning pharmacology, efficacy and safety profile of clobetasol-17 proprionate, updated studies on its use, efficacy of different formulations and impact on quality of life in corticosteroid-responsive dermatoses.

Sign in / Sign up

Export Citation Format

Share Document